Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2016 by Boston Scientific Corporation
Information provided by (Responsible Party):
Boston Scientific Corporation Identifier:
First received: October 2, 2012
Last updated: January 8, 2016
Last verified: January 2016
The purpose of this study is to demonstrate that preoperative biliary drainage using self-expanding metal stents (SEMS) does not negatively impact overall surgical outcomes in patients undergoing pancreaticoduodenectomy for treatment of pancreatic or periampullary cancer.

Condition Intervention Phase
Pancreatic Carcinoma
Device: WallFlex™ Biliary RX Fully Covered/Uncovered Stent System
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomized Multi-Center Study Comparing No Drainage to Preoperative Biliary Drainage Using Metal Stents in Patients With Resectable Pancreatic or Periampullary Cancer

Resource links provided by NLM:

Further study details as provided by Boston Scientific Corporation:

Primary Outcome Measures:
  • Number of serious pre-operative, operative and post-operative adverse events to 120 days post randomization or to 30 days post surgery, whichever comes last [ Time Frame: 120 days ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Number of adverse events [ Time Frame: Procedure - 120 days ] [ Designated as safety issue: Yes ]
    Adverse events will be assessed in terms of rate, severity, seriousness, relatedness to stent or endoscopic or surgical procedure, impact on time of surgery, length of hospitalization and ICU stay.

  • Time to surgery [ Time Frame: Baseline to 4 weeks ] [ Designated as safety issue: No ]
  • Curative Intent Surgery details pertaining to intraoperative assessment of resectability, surgical resection and reconstruction techniques. [ Time Frame: Baseline to 4 weeks ] [ Designated as safety issue: No ]
  • Amount of intraoperative blood loss and number of blood transfusions, duration of surgery [ Time Frame: At time of surgery ] [ Designated as safety issue: No ]
  • Biliary obstructive symptoms assessment [ Time Frame: Baseline - 120 days ] [ Designated as safety issue: No ]
  • Improvement of liver function test (LFT) levels as relative to baseline [ Time Frame: Week 2 - 120 days ] [ Designated as safety issue: No ]
  • Stent placement success [ Time Frame: Procedure ] [ Designated as safety issue: No ]
    Stent placement success: ability to deploy the stent in satisfactory position across the stricture (For patients who are randomized to biliary drainage with a metal stent)

  • Stent removal success [ Time Frame: At time of surgery or prior to surgery if re-intervention is needed. ] [ Designated as safety issue: No ]
    Stent removal success: successful SEMS removal, either en bloc at time of surgery or endoscopically prior to surgery without stent removal related SAEs (For patients who are randomized to biliary drainage with a metal stent)

  • Number, type, reason, and timing of biliary re-interventions [ Time Frame: Baseline - 120 days ] [ Designated as safety issue: No ]
  • Number of hospital and ICU admissions [ Time Frame: Procedure - 120 days ] [ Designated as safety issue: No ]
  • Duration of hospital and ICU admissions [ Time Frame: Procedure - 120 days ] [ Designated as safety issue: No ]

Estimated Enrollment: 294
Study Start Date: February 2013
Estimated Study Completion Date: September 2019
Estimated Primary Completion Date: July 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: WallFlex™ Biliary RX Fully Covered/Uncovered Stent System
Patients in this group will receive a fully covered or uncovered study SEMS (self-expanding metal stent)
Device: WallFlex™ Biliary RX Fully Covered/Uncovered Stent System
No Intervention: None (No Pre-Operative Biliary Drainage)
Patients in this group will not receive pre-operative biliary drainage with a study SEMS


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 or older
  • Willing and able to comply with the study procedures and provide written informed consent to participate in the study
  • Diagnosis of probable pancreatic cancer, distal common bile duct (CBD) cholangiocarcinoma and other periampullary cancers (histology not required)
  • Biliary obstructive symptoms or signs
  • Bilirubin level at/above 100 umol per liter (5.8 mg/dL)
  • Distal biliary obstruction consistent with pancreatic cancer, distal CBD cholangiocarcinoma or other periampullary malignancy
  • Location of distal biliary obstruction is such that it would allow the proximal end of a stent to be positioned at least 2cm from the hilum
  • Patients deemed as resectable by pancreatic protocol CT or MRI
  • Surgical candidate per pancreatobiliary surgeon after multi-disciplinary discussion
  • Surgery intent within 4 weeks
  • Endoscopic and surgical treatment to be provided by same team

Exclusion Criteria:

  • Biliary strictures caused by confirmed benign tumors
  • Biliary strictures caused by malignancies other than pancreatic cancer, distal CBD cholangiocarcinoma and other periampullary cancers
  • Surgically altered biliary tract anatomy, not including prior cholecystectomy
  • Neoadjuvant chemotherapy for current malignancy
  • Palliative indication due to reasons other than surgical candidate status
  • Previous biliary drainage by ERCP/PTC
  • Patients for whom endoscopic techniques are contraindicated
  • Participation in another investigational trial within 90 days
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01774019

Contact: Lina Ginnetti 508-683-4512
Contact: Talia Romano 508-683-6132

United States, California
Standford University Medical Center Not yet recruiting
Stanford, California, United States, 94305
Contact: Benjamin Priestley    650-723-2990   
Principal Investigator: Brendan Visser, MD         
United States, Indiana
Indiana University Medical Center Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Suzette Schmidt    317-948-8104   
Contact: Sheryl Lynch    317-944-4228   
Principal Investigator: Stuart Sherman, MD         
Australia, New South Wales
Westmead Hospital Recruiting
Westmead, New South Wales, Australia, 2145
Contact: Laura Bokody   
Principal Investigator: Michael Bourke, MD         
ULB Erasme Hospital Recruiting
Brussels, Belgium, 1070
Contact: Mona Hammam    32 25 55 36 22   
Principal Investigator: Jacques Devière, MD         
Canada, Quebec
Centre hospitalier de l Université de Montréal Withdrawn
Montreal, Quebec, Canada, H2X 3J4
Prince of Wales Hospital, the Chinese University of Hong Kong Recruiting
Hong Kong, China
Contact: Kim Au   
Principal Investigator: James Lau, MD         
Hopital Edouard Herriot Recruiting
Lyon, France, 69437
Contact: Hadjira Ouadfel    +33-610133675   
Principal Investigator: Thierry Ponchon, MD         
Asian Institute of Gastroenterology Recruiting
Hyderabad, India, 500 082
Contact: Mukta Singh    +91-9441474270   
Principal Investigator: Nageshwar Reddy, MD         
Università Cattolica del Sacro Cuore Policlinico A. Gemelli Recruiting
Rome, Italy, 00168
Contact: Carolina Gualtieri    +39 (06) 35511515   
Principal Investigator: Guido Costamagna, MD         
Tokyo Medical University Recruiting
Tokyo, Japan, 160-0023
Contact: Takao Itoi, MD    81-3-33426111   
Principal Investigator: Takao Itoi, MD         
Sponsors and Collaborators
Boston Scientific Corporation
Principal Investigator: Guido Costamagna, MD Catholic University of the Sacred Heart
  More Information

Responsible Party: Boston Scientific Corporation Identifier: NCT01774019     History of Changes
Other Study ID Numbers: CDM00047339  E7059 
Study First Received: October 2, 2012
Last Updated: January 8, 2016
Health Authority: Australia: Department of Health and Ageing Therapeutic Goods Administration
Belgium: Federal Agency for Medicinal Products and Health Products
Canada: Health Canada
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Hong Kong: Department of Health
India: Ministry of Health
Italy: Ministry of Health
Japan: Institutional Review Board

Keywords provided by Boston Scientific Corporation:
Periampullary Cancer
Preoperative Biliary Drainage

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Neoplasms by Site
Pancreatic Diseases processed this record on May 26, 2016